Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.61 USD | +8.05% | +36.44% | -21.08% |
Jun. 12 | Sector Update: Health Care Stocks Rise Premarket Wednesday | MT |
Jun. 12 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of US FOMC Announcement | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.08% | 180M | |
+19.36% | 80.64B | |
+15.93% | 9.07B | |
+42.06% | 4.68B | |
-22.01% | 4.53B | |
+8.28% | 4.06B | |
-26.61% | 2.21B | |
+11.22% | 2.19B | |
+11.64% | 2B | |
-42.69% | 1.82B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023